pharma · Not applicable, Healthy Volunteers · advanced/metastatic non-squamous non-small cell lung cancer (NSCLC)
mAbxience
Mabxience Research SL
mAbxience clinical programs — 5 development programs from ClinicalTrials.gov with phase, modality, indication, and trial identifiers.
Company details
- Status
- Public
- HQ
- madrid, ES
- Founded
- 2009
- Employees
- 1,194
- Programs
- 5
- Drugs
- 10
- Patents
- 0
mAbxience projects
5 ClinicalTrials.gov programs sponsored by mAbxience.
mAbxience has 5 clinical development programs indexed from ClinicalTrials.gov, including phase, modality, indication text, and linked NCT identifiers.
Clinical programs
-
MB04-C-01-23
Mabxience Research SL
Rheumatoid Arthritis
1 trial -
MB11-C-01-25
Mabxience Research SL
Previously Untreated Advanced (Unresectable or Metastatic) Melanoma
1 trial -
MB12-C-02-24
Mabxience Research SL
advanced/metastatic non-squamous non-small cell lung cancer (NSCLC)
1 trial -
MB02-SP
Mabxience Research SL
Healthy Volunteers
1 trial -
MB04-A-01-23
Mabxience Research SL
Not applicable, Healthy Volunteers
1 trial
Frequently asked questions
How many clinical projects does mAbxience have?
5 published programs are linked to this sponsor in our ClinicalTrials.gov index.
Is this the complete company pipeline?
This directory lists published programs for the sponsor in our database. Partnered or out-licensed assets may appear under multiple companies.